about
Ganglion cell death in glaucoma: what do we really know?5-Hydroxytryptamine1A agonists: potential use in glaucoma. Evidence from animal studies.Expectations in the treatment of retinal diseases: neuroprotection.Pharmacodynamics of citicoline relevant to the treatment of glaucoma.Selective serotonin reuptake inhibitors: a review of its effects on intraocular pressureVaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucomaPharmacotherapy of glaucoma.Functional and structural changes in a canine model of hereditary primary angle-closure glaucomaReducing intraocular pressure: is surgery better than drugs?The effect of melatonin on retinal ganglion cell survival in ischemic retinaRole of melatonin in the eye and ocular dysfunctions.Hypoxia-ischemia and retinal ganglion cell damage.Associations of sleep duration with open angle glaucoma in the Korea national health and nutrition examination survey.The potential of stem cell research for the treatment of neuronal damage in glaucoma.Current Concepts in the Biochemical Mechanisms of Glaucomatous Neurodegeneration.Betaxolol, a beta(1)-adrenoceptor antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: comparison with other beta-adrenoceptor antagonists.Neuroprotective Effects of Memantine in the Retina of Glaucomatous Rats: An Electron Microscopic Study.Neuroprotective effect of nipradilol on axotomized rat retinal ganglion cells.Effect of retinal ischemia on the non-image forming visual system.Oral treatment with the melatonin agonist agomelatine lowers the intraocular pressure of glaucoma patients.
P2860
Q24673200-9DF63D0B-6243-42A5-BACF-D1A15B851265Q34057619-7D57D9C1-24CC-459A-9FCC-BA932B0BB72DQ34404709-97CDFB77-0612-45B4-862F-88BE7598AD42Q34488157-FEB93CBB-69F6-41A2-8160-FDE4B9B8A1FEQ34658800-7287B843-7930-4E69-94A0-8B587C88CE96Q34734517-29DC877C-2B13-41F4-83C1-65A6360C236EQ35138049-E7CA5CCD-C052-44D0-BBA7-F53424CA8A41Q35673897-39A0532E-BF3E-46FE-9571-1BBC75E649AFQ35750072-88C55297-B574-4460-B878-8156FD85B137Q36211872-8A8994B0-87BF-4B9C-880F-824BE2F137DCQ36724212-D7304A9B-0922-4A89-A7B6-32F29E55369DQ37236104-7830B7A1-ECE8-442A-96B4-D435F94DD07EQ37552148-F94E69F2-8ECE-41F5-A93E-1F063C8B85CAQ38109499-20F51F3B-9E31-4BA9-B204-E5F949FA5457Q38258778-6FCBF45E-E25D-45BA-B815-2CC347900807Q41903223-97914CE5-CA26-458F-B9DE-9F5D6B7A17A5Q42511040-8C8DB8AC-564F-4AF7-A28F-C4A10B45DFA1Q44108811-831E8388-61C0-4FFD-8001-63F8DDB5E848Q48530246-7F33425B-F3BF-4CBD-9AD6-FA595724C014Q53634760-EFF435EE-04BA-43AC-AB3E-A9A923EC8287
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
The potential of neuroprotection in glaucoma treatment.
@ast
The potential of neuroprotection in glaucoma treatment.
@en
type
label
The potential of neuroprotection in glaucoma treatment.
@ast
The potential of neuroprotection in glaucoma treatment.
@en
prefLabel
The potential of neuroprotection in glaucoma treatment.
@ast
The potential of neuroprotection in glaucoma treatment.
@en
P2093
P1476
The potential of neuroprotection in glaucoma treatment.
@en
P2093
P356
10.1097/00055735-199904000-00002
P577
1999-04-01T00:00:00Z